(AOF) – Boiron announces a turnover for the second quarter of 2023 down 3.1% to 110.9 million euros. The laboratory specializing in homeopathy notes that “restated for the drop in sales of Covid tests”, this turnover is “up 1.3%”. The 2.6% decrease in sales of nonproprietary homeopathic medicines “is still mainly attributable to France”, he underlines: “sales continue to progress in many other countries, particularly in the United States”.
The decline in sales excluding homeopathy “continues and is explained by the drop in sales of Covid tests in Europe, particularly in France”.
Similarly, if sales fell by 6.6% over the half-year, it is because they were impacted by the base effect from the significant sales of Covid tests made in France in the first half of 2022. ” Excluding Covid tests, sales are up by 6.2% ” notes the group.
The evolution of the Group’s sales in 2023 “will depend on the continuation of the current momentum in homeopathic specialties, future launches and the level of pathology at the end of the year” concludes Boiron soberly.
The group’s family shareholders announced a simplified takeover bid in early July. The operation values the Boiron title at 50 euros. The simplified tender offer would be made at a price of 39.64 euros per share, after deduction of an exceptional dividend of 10.36 euros per share.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.